Remicade

Known as: Remicade [brand name] 
brand name of infliximab a drug used to treat autoimmune disorders
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
OBJECTIVE The cross-immunogenicity of the recently approved infliximab-biosimilar Remsima (CT-P13) with the originator drug… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
BACKGROUND AND AIMS The biosimilar of Remicade®, CT-P13, recently entered the European market. Clinical data on switching from… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in patients with rheumatoid arthritis… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2010
2010
PURPOSE To determine the tolerability of intravitreal infliximab (Remicade) in patients with refractory diabetic macular edema or… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Necrosis of skeletal muscle fibers in the lethal childhood myopathy Duchenne muscular dystrophy (DMD) results from defects in the… (More)
Is this relevant?
2004
2004
Necrosis of skeletal muscle fibers in the lethal childhood myopathy Duchenne muscular dystrophy (DMD) results from defects in the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
Remicade, a chimeric human-murine monoclonal antibody capable of neutralizing tumor necrosis factor alpha was given to 37 low… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
OBJECTIVE When one TNFalpha blocker (etanercept or infliximab) has failed, to determine whether it makes sense to treat patients… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
OBJECTIVE The cost per quality-adjusted life-year (QALY) of infliximab (Remicade) treatment in rheumatoid arthritis (RA) was… (More)
Is this relevant?
2003
2003
TO THE EDITOR: We report an unusual case of a 45-yrold woman who developed branch retinal vein thrombosis after receiving… (More)
  • figure 1
Is this relevant?